Massive Bio, a global precision oncology company, today announced the publication of a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology demonstrating that its ...

The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation. About Taletrectinib Taletrectinib is an oral, potent, central nervous system-active, ...

Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...

SAN DIEGO--(BUSINESS WIRE)--Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a ...

This ambitious program leverages Massive Bio’s AI capabilities and Trial Command Center to significantly accelerate oncology clinical research and bring clinical trial access to the masses NEW ...

Massive Bio, a cancer patient matchmaker, has been selected by the Precision Cancer Consortium to help identify potential candidates for clinical trials. The consortium, founded in 2022, is focused on ...

NEW YORK, May 13, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new ...

(MENAFN- EIN Presswire) EINPresswire/ -- Massive Bio Publishes Peer-Reviewed Prospective Study Demonstrating AI Clinical Trial Matching Four Times Faster Than Conventional Methods Study in ESMO Real ...

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison ...